News on COVID-19 vaccine has become an every Monday recurring decimal. Tying to change the market dynamics at all cost. Maybe we should always wait for Moderna news before planning weeks' trades.
*MODERNA SET TO FILE FOR U.S., EU CLEARANCE FOR COVID-19 VACCINE— @sellvolbuytesla (@sellvolbuytesla) November 30, 2020
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). The Company also announced that today, Moderna plans to request an ... (full story)